Avaleht › Lümfoom › Texas › Houston
Lümfoom kliinilised uuringud linnas Houston, TX
34 uuringut haiguse Lümfoom jaoks otsivad osalejaid linnas Houston ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
VärbamineFaas 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
VärbamineVaatlusuuring
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
VärbamineFaas 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
VärbamineFaas 2
- MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
VärbamineFaas 1/2
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
VärbamineFaas 1
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
VärbamineFaas 1/2
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
VärbamineFaas 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
VärbamineFaas 3
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
VärbamineFaas 1
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
VärbamineFaas 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
VärbamineFaas 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
VärbamineFaas 1/2
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
VärbamineFaas 2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
VärbamineFaas 1
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
VärbamineFaas 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
VärbamineFaas 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
VärbamineFaas 1
- The University of Texas M D Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
VärbamineFaas 2
- MD Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
VärbamineFaas 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
VärbamineFaas 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
VärbamineFaas 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
VärbamineFaas 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
VärbamineFaas 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
VärbamineFaas 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
VärbamineFaas 1/2
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
VärbamineVaatlusuuring
- M D Anderson Cancer Center, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Värbamine
- MD Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
VärbamineVaatlusuuring
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
VärbamineFaas 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
VärbamineFaas 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
VärbamineFaas 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
VärbamineFaas 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
VärbamineFaas 1
- The University of Texas MD Anderson Cancer Center, Houston
Lümfoom uuringud teistes linnades
- Boston, MA33 uuringut
- New York City, NY33 uuringut
- Washington, DC23 uuringut
- Baldwin Park, CA21 uuringut
- Chicago, IL20 uuringut
- Durham, NC17 uuringut
- St. Louis, MO15 uuringut
- Philadelphia, PA15 uuringut
- Cleveland, OH14 uuringut
- Edison, NJ12 uuringut
- Atlanta, GA12 uuringut
- Seattle, WA12 uuringut
Muud uuringud linnas Houston
- Mitteväikerakuline kopsuvähk145 uuringut
- Rinnavähk126 uuringut
- Vähk (kõik liigid)121 uuringut
- Metastaatiline vähk104 uuringut
- Käär- ja pärasoolevähk102 uuringut
- Munasarjavähk89 uuringut
- Äge müeloidne leukeemia85 uuringut
- Kopsuvähk78 uuringut
- Eesnäärmevähk76 uuringut
- Endomeetriumivähk68 uuringut
- Pankreasevähk61 uuringut
- Melanoom59 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.